Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (84)	2/14/2000 8:52:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 447

<<Can't believe that I've won on both sides of the old battle, Sibia versus KDUS, and that I'm winning now that the Cadus assets have been purchased. Three for three, and all because I had a few beers with you.>> Now, I am realising that KDUS assets are much more than I ever thought. Thanks for help on this from KDUS analysis. Adenosine receptors are again HOT. This is new opportunity for OSIP. I have to give credit C. Goddard on this one. Miljenko